Samsung Bioepis receives European approval for Enbrel biosimilar to treat RA

Samsung Bioepis receives European approval for Enbrel biosimilar to treat RA

Samsung Bioepis Co., Ltd, a biopharmaceutical company, announced the European Commission's (EC) approval of Benepali – a biosimilar referencing Enbrel (etanercept), also known as SB4 – for the treatment of rheumatoid arthritis, psoriatic arthritis

(Visited 1 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.